Bisoprolol
Mostrando 1-7 de 7 artigos, teses e dissertações.
-
1. Substituição do carvedilol pelo propranolol em pacientes com insuficiência cardíaca
FUNDAMENTO: Grandes estudos clínicos empregando os betabloqueadores carvedilol, metoprolol, bisoprolol e nebivolol, demonstraram melhora da sobrevida e dos sintomas em pacientes com insuficiência cardíaca. Apesar da falta de evidências científicas, é plausível que o efeito benéfico seja extensível a outros betabloqueadores. OBJETIVO: Avaliar em paci
Arquivos Brasileiros de Cardiologia. Publicado em: 11/06/2010
-
2. Efeito do bisoprolol sobre a função cardíaca e o exercício em pacientes com insuficiência cardíaca
OBJETIVO: Avaliar o efeito do bisoprolol sobre a capacidade de exercício e a função ventricular em pacientes com insuficiência cardíaca. MÉTODOS: Foi feita a análise das variáveis clínicas e hemodinâmicas, da função e do remodelamento ventricular, e da ergoespirometria de pacientes com insuficiência cardíaca com diferentes etiologias, antes e a
Arquivos Brasileiros de Cardiologia. Publicado em: 2007-03
-
3. Beta-adrenergic blocking agents in heart failure
Cardiac dysfunction in heart failure is widely recognized as a progressive process, regardless of the clinical signs and symptoms. An increase in cardiac sympathetic drive is one of the earliest neurohormonal responses occurring in patients with heart failure and may be one of the major causes of the progressive remodeling leading to the decline in myocardia
Arquivos Brasileiros de Cardiologia. Publicado em: 2000-10
-
4. Beta adrenoreceptor subtype cross regulation in the human heart.
OBJECTIVES--To find out in a prospective study whether beta 1 blocker treatment causes selective beta 2 adrenoreceptor sensitisation, and to find whether such sensitisation is confined to the heart. DESIGN--A placebo controlled cross over study of two weeks of selective beta 1 blocker treatment with 10 mg of bisoprolol daily. SUBJECTS--Six healthy volunteers
-
5. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
Previous trials (Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure [MERIT-HF], Cardiac Insufficiency Bisoprolol Study [CIBIS] II) have demonstrated a mortality benefit of β-adrenergic blockade in patients with mild to moderate heart failure. The recent Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial has exte
BioMed Central.
-
6. Debate: Do all patients with heart failure require automatic implantable defibrillators for the prevention of sudden death?
Recent clinical trials indicate that approximately two-thirds of patients in New York Heart Association (NYHA) class II and III, who comprise almost 90% of patients with heart failure, die suddenly. Patients in NYHA class IV usually die of progressive heart failure. Implantation of implantable cardioverters defibrillators (ICDs) in this population would repr
BioMed Central.
-
7. Reduced beta-adrenergic receptor activation decreases G-protein expression and beta-adrenergic receptor kinase activity in porcine heart.
To determine whether beta-adrenergic receptor agonist activation influences guanosine 5'-triphosphate-binding protein (G-protein) expression and beta-adrenergic receptor kinase activity in the heart, we examined the effects of chronic beta 1-adrenergic receptor antagonist treatment (bisoprolol, 0.2 mg/kg per d i.v., 35 d) on components of the myocardial beta